CURRICULUM VITAE in Inglese
Name Giulio (Filippo, Giacomo) Tarro
Date of birth 09, 07,1938
Place of birth Messina, Italy
Home Address via Posiliipo 286, 80123 Naples, Italy
Office Foundation T. & L. de Beaumont Bonelli for cancer research, Via G. Palermo 112, 80131 Napoli Italy
Home Phone and fax +39.081.5750090
Office Phone +39339.3535847 +39.081.5463222
Mobile Phone +39.335.7758241 +39.337.972238
E-mail firstname.lastname@example.org email@example.com
- 1944 -1956- Elementary and High School, Messina, Italy
- 1962 – Medical Degree summa cum laude, University of Naples
- 1968- Diploma of Specialist in Nervous and Mental Diseases summa cum laude, University of Naples
- 1970- Professorship (“Libera Docenza,,) in Virology, Rome
- 1963 – Board Examination, Naples
- 1975 – Virology Head Examination, Rome
- 1975 – Italian Navy Major
- 1982, 1984, 1995 – Course at NavyAcademy of Leghorn
- 1993 – Lieutenant Colonel Trajnjng
- 1957-1960 – Pregraduate Fellow, Institute of Anatomy, University of Messina: Prof. Zaccaria Fumagalli
- 1960-1962 – Pregraduate Fellow, Institute of Pathology, University of Naples: Prof. Flaviano Magrassi
- 1963-1964- Postgraduate Fellow, Institute of Pathology, University of Naples
- 1964-1966 – Assistant, Institute of Pathology, University of Naples
- 1965-1968 – Research Associate, Division of Virology and Cancer Research, The Children’s Hospital Research Foundation, Cincinnati, Ohio: Albert B. Sabin, M.D.
- 1968-1969 – Assistant Professor of Research Pediatrics, University of Cincinnati, College of Medicine
- 1966-1974 – Italy National Research Council Fellow; Research Chief( 1974 )
- 1971-1985 – Professor of Oncologic Virology, University of Naples, l st College of Medicine
- 1971-1975 – Project Director (National Cancer Institute, Bethesda. Md, U.S.A.) Research Contract n. 712056 (1971-1972) and n. NO1 CP33315 (1973-1975)
- 1972- to date Professor of Microbiology and Immunology at the School of Specialization in Medical Nephrology, Ist College of Medicine then 2nd University of Naples (S.U.N.)
- 1973 – to date Chief, Division of Virology, “D. Cotugno” Hospital for Infectious Diseases
- 1973- Senior Scientist, N.C.I., FrederickCancerResearchCenter, Fort Detrick, Frederick; Maryland
- 1975-1979 – Representative of the Education Minister in the Scientific Committee of the Zoological Station (Aquarium) of Naples
- 1978 – Life President of the “Teresa and Luigi de Beaumont Bonelli Foundation for Cancer Research” (Italian Presidential Decree, Jan. 3, 1978)
- 1995-98 Member of National Commitee on Bioethics
- 1998 – to date – President Ethic Committee of D.CotugnoHospital
- 2000-2003 Scientific Coordinator of Extracorporeal Hyperthermia in HCV Patients, First Circle
Med., Minneapolis, USA
- 2003 – to date – Head Department of Diagnostic Laboratories of D.Cotugno Hospital
- 2004 – to date President of “Campania Technology and EcologyCenter”
- 2005 Vice-Chairman and General Secretary of the Scientific Advisory Board of Unihart Biotech Pharma, N.V. (www.unihart.com)
- 2005 – Member of Ethic Committee of Basilicata Oncologic Hospital
- 2006 – Emeritus Chief, D. Cotugno Hospital for Infectious Diseases
- 2007 – Chairman Committee on BioTechnologies and VirusSphere, World Academy of Biomedical Technologies (WABT), UNESCO – Paris
● 2007 – Adjunct Professor Department of Biology, Center for Biotechnology – College of Science and Technology, TEMPLEUNIVERSITY – PhiladelphiaUSA
- Murine Virology
- Antiviral Chemotherapy
- Effects of inhibitors on viraI replication
- Studies on the role of herpesviruses in cancer
- Tumor immunology
- Pathology of AIDS
- Who’s who in the World, from 10th to 24nd Edition, Marquis 1991-92 to 2013;
- Who’s who in Italy , from 1992 edition to 2005-2006 edition Sutter’s International Red Series;
- Who’s who in America, from 47th to 61st Edition, Marquis 1992 to 2013;
- Who’s who in Science and Engineering, from 1st to 9th Edition, Marquis 1992-93 to 2006-07;
- Who’s who in Medicine and Healthcare, from 1st to 7th Edition, Marquis 1997-98 to 2011-12;
- Who’s who in Finance and Industry (Business), from 32nd to 36th Edition, Marquis 2001-02 to 2006-07;
- International Who’s who of Professional, Gibralter Publishing, INC. 1998; 1999; 2000;
- Grand Ambassadors of Achievement International 3rd Edition (ABI) 1993
- International Who’s who of Intellectuals, International Biographical Centre, (IBC) X Edition, Cambridge 1993-94.
- International Who’s who in Medicine, 2nd Edition, Intern. Biographical Centre Cambridge, England April 1994.
- Who’s who in European Research and Development, Bowker-Saur, England 1995
- Who’s who in Professional ed. 2004-2005
- Who’s who in Historical Socjety, ed. 2001-2002
- Who’s who in Madison, ed. 2004-2005.
- The Barons 500 Who’s who: Leaders for the New Century, 1999; 2000: 2001
- Five thousand Personalities of the World, American Biographical lnstitute (A.B.I.), 1994; 1996; 1998
- International Directory of Distinguished Leadership, American Biographical lnstitute (A.B.I.), 4th Edition 1992; 5th Edition 6th Edition;
- Five hundred Leaders or Influence, American Biographical lnstitute (A.B.I.), 1993;
- Dictionary or International Biographical Centre, (IBC) XXII Edition, XXII Edition, Cambridge 1993; 1995
- Men or Achievement, International Biographical Centre, (IBC) XV Edition 1992; XVI Edition; XVII Edition, Cambridge:
- European Biographical Directory, 10th Edition.
- 500 Distinguished Professors of the BWW Society by J. Pellam, Irvine, California (USA) 2002; 2003
- American Chemical Society (since 2005)
- American Society for Microbiology (since 1967)
- American Association for the Advancement of Sciences (since 1969)
- New YorkAcademy of Sciences (since 1973)
- International Association for Comparative Research on Leukaemia and Related Diseases
- ltalian Society for Microbiology
- Italian Cancer Society
- ltalian Society for lmmunology and Immunopathology
- Italian Society for lnfectious Diseases
- Interdisciplinary Group of Scientific Parapsycology (honorary member)
- Italian Society of Colposcopy and Cervical-Vaginal Pathology (honorary member)
- Italian Society of Immuno-Oncology (since 1990 president)
- International League “Doctors for the Abolition of Vlvisection” (since 1992 president)
- European Society for Clinical Virology.
- Member of Board of Directors Neuroimmuno Therapeutics Research Foundation, Spartanburg, USA
- Member or the American Biographical Institute Research Board of Advisors
- Corresponding Member or the American Association for Cancer Research (since 1997)
- Italian Society of Neurology
- AIDS Society of Asia and the Pacific
- UNESCOHebrewUniversity of JerusalemInternationalSchool for Molecular Biology and Microbiology
- Member of Honorary Committee of Eur.Academy for the Economical and Cultural Relationships, Rome;
- Member of Scientific Medical Committee of Social Centre, Kiev – Ukraine;
- Environment Medical Doctors Association . ISDE – Italy;
- Italian Association for Viral Study and Research (president since 1995, hon. presid. 2009)
- International Society for Neurovirology
- · Member of the Scientific Commitee of <<Convivia Medica>> (Rome).
- · Member of the Scientific Commitee of <<Panorama Scientifico>> (Naples).
- · Member of the Editorial Commitee of <<Nuovo Bollettino di Farmacologia Clinica” – Consorzio Regionale Farmaceutico Ospedaliero>> (Naples).
- · Member of the Scientific Commitee of <<Neurologia Psichiatria Scienze Umane>> (S. Maria a Vico - Caserta).
- · Honorary Scientific Co-Editor of <<Igea Medica>> (Avellino)
- · Honorary Member of <<Rassegna Medico-Chirurgica>> (Benevento)
- · Member of the Scientific Commitee of <<Ricerca Medica>> (Naples)
- · Scientific Coordinator of <<Italian Review of MedicaI and Surgical Researches>> (Naples)
- · Editor (since 2000) of <<International Journal or Clinical Investigation >> I.J.C.I., Naples
- · Editor (since 2003) of <<Cotugno News>>Naples
- · Editor (since 2004) of <<Fratres>> Journal of the Blood Donors, Florence
Awards and Honors
- 1963 Lepetit Award for Medical Degree, University of Naples
- 1965, 1966 “A. B. Sabin” Prize (U.S. dollars 3,000 each) from SCLAVO Institute, Siena
- 1967 U.S. dollars 5,000 Award from Italian Pharmacotherapic Institute
- 1969 “G. Lenghi” International Award of the National Academy of Lincei (Rome) for ViraI Studies (Former winner S. Stewart)
- 1971 “D. De Blasi” National Award from Richardson Merrel
- 1973 “Gold Microscope” International Award from Italian Health Minister (Former winners.A. B. Sabin, S. Luria)
- 1973,1975 G. D’Orso National Award (Naples) (AIso winner R. Dulbecco)
- 1975 “Gold Jumbo Jet” International Award at Capitolium Rome (Former winner D. Bovet)
- 1975 Gold medal from the President of Italian Republic for achievements in public education
- 1976 Knights of Humanity International Award, Malta
- 1978 International Universum Award for Medicine from the International Center of Solidarity “Giovanni XXIII” (Former winner C. Barnard)
- 1978 Gold medal and honorary member, International Academy of Pontzen
- 1979 Gold medal and director for MedicaI Science, Academy of Paestum
- 1979 Diploma and academician title from the RomanAcademy of medical and biological Sciences, Capitolium (Rome)
- 1979 Gold Lion National Award from the Lion Brigade, Pistoia (Former winner: famous Italians in Art, Culture and Sciences)
- 1979 Special honour and title (Commendatore of Grace,,) from Sovereign Order of Saint John of Jerusalem, Malta (Knights of Malta,)
- 1979 Special honour and title (Comm. of Masterly Grace) from Order of S. Brigitte of Svevia
- 1981, 1986 Tifeo Award for science and Medicine from International Center of Culture, Rome-lschia
- 1982 National Award for Sciences, under the patronage of Health Minister, at Capitolium, Rome
- 1983 Special honour and title (“Great Official of Masterly Grace,,) from Sovereign Order of S. George in Carinthia (Karrnten)
- 1983 Star of Europe Award for European Cavalier Union, Rome
- 1983 International Prize “Riace Warriors” from the Templari, Culture Society
- 1983 National Award of the South “Gold Marmaid” of Palinuro for medical studies, under the patronage of the President of the ItalianRepublic
- 1985 National Award for the Culture from the Presidenza del Consiglio dei Ministri
- 1987 First Prize in Biomed. Research, ItalianAcademy of Arts and Sciences
- 1989 Laurea Honoris Causa in MedicineCatholicUniversity, Albany, New York
- 1990 Member of Academic Senate of Costantinian University, Providence, Rhode lsland, USA
- 1991 Laurea Honoris Causa in Immunology, St. Theodora Academy, New York
- 1991 Castello di Pietrarossa Award, Caltanisetta (also Winner H.H. Fudenberg)
- 1991 Decorated Comdr. ltalian National Order of Merit
- 1992 International Award “Cesare d’oro”, Padova
- 1994 Member of Academy Senate Pro Deo University, New York
- 1994 Kinght Grand Cross Sovereign Constantinian Order St. George
- 1994 Gold Little Horse, Transnational. European Federation, Rome
- 1995 Laurea Honoris Causa in Bioethics, ConstantinianUniversity, Cranston, Rhode Island
- 1996 King Manfredi award, Manfredonia
- 1999 Equestris Ordinis S. Sepulcri of Jerusalem, Rome
- 1999 Gold medal of health PresidentItalianRepublic, Rome
- 1999 GreatOfficerItalianRepublic Order of Merit
- 1999 Saint Catherin Award, Siena
- 2001 Honorary academic Member University Sancti Cyrilli, Valletta, Malta
- 2003 Honorary Rector Ruggiero II University, Florida
- 2003 Sorrento in the World Award, Sorrento
- 2005 Medal of Minister for Culture, Viareggio
- 2006 Knight of Solidarity Internat. Award Norman Acad., Rome
- 2006 Saint Pio for Peace award City of Fiuggi.
- 2006 Tables of Law award Internat. Assn. Cath. Apostleship, Naples.
- 2007 Casentino award for medicine, Poppi, Arezzo
- 2008 Award Pres. Italian Rep., silver medal
- 2009 Lifetime Achievement award, Sbarro Health Research Orgn. Philadelphia
- 2010 Grand Prix Solidarite Dem. Rep. Congo
- 2010 National award for solidarity Fratres St. Giovanni La Punta
- 2011 Global Education Sanremo award
- 2011 International Peace Award
- 2012 AAAS member Royal House Aranan (Philippine) (Gold medal)
- 2012 International Prize Le Muse Florence
1) “Antigenic regions of Tumor Liberated Particles (TLP) complexes and antibodies”.
Priority date(s): IT July 7, 1992. Europe: Patent No. EP649433 granted on November 19, 1997 and validated in the following countries: Austria, Belgium, Denmark, France, Germany, Ireland, Nethelands, Portugal, Spain, Sweden, Switzerland, United Kingdom. Eurasia & AsiaAustralia: Patent No. 680198, granted on 11/13/97;Russian Federation: Patent No. 2141969, granted on 4/21/99;South Korea: Patent No. 237250 granted on 10/10/99. US, Canada, Mexico and BrazilUnited States: 1) Patent No. 5759792, granted on 6/2/98; 2) Patent No. 5747643, granted on 5/5/98; 3) Patent No. 5877294, granted on 3/2/99; Canada: Patent No. 2139518, (“Notice of allowance” dated 01/10/2003).
2) “Pharmaceutical compositions comprising natural human interferon”
Priority dates: 02/28/1996, 6/14/1996) Patents IssuedEurope European Patent No. 0.886.527, granted on 9/12/01: Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Liechtenstein, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom. Other countries:Australia: Patent No. 722987, granted on November 30, 2000; Eurasia (Armenia, Azerbaijan, Belarrus, Kyrgyzstan, Kazakhstan, Maldava, Tajikistan, Turkmenistan): Patent No. 001147, recently granted (the granting date is not yet available). Georgia: Patent No. 2489, granted on July 25,2001; Italy: 1) Patent No. 1.283.945, granted on May 7, 1998; 2) Patent No. 1.284.852, granted on May 22, 1998.North Korea: Patent No. 33639, granted on December 24, 1999;Russian Federation: Patent No. 001147, recently granted (see “Eurasia”);
3) “Urogenital carcinoma TLP complex peptides and antibodies thereof”.
Priority date(s): IT October 10 1996. Europe: Patent No. EP851872 granted on April 18, 2001 and validated in the following countries: Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom.
4) “Immunogenetic TLP composition”
Priority date(s): IT July 10, 1996.Europe: Patent No. EP938329 granted on May 29, 2002 and validated in the following :Austria, Belgium, Denmark, France, Germany, Ireland, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom. Other countries: Australia: Patent No. 725218, granted on January 25, 2001.Russian Federation: Patent Applications No. 2192274, granted on November 10, 2002.
5) “Sticking plaster for controlled release of natural interferon”
Priority date(s): see PCT application. International Patent Application No. PTC/EP98/03809, filed on June 22,1998, has been extended in the following countries: Australia, Canada, China, Europe, Japan, Mexico, New Zelanda, Norway, U.S.A. The International Preliminary Examination Report, issued at the end of the PCT procedure, has expressed a favourable opinion with regard to novelty, inventiveness and industrial applicability. Austria: Patent No. 84396/98 has been allowed and the corresponding Patent issued shortly. New Zelanda: Patent No. 509029 has been allowed and the corresponding Patent issued shortly.
6) “Transdermal pathch and tropical compositions comprising propylnorapomorhine”.
Priority date(s): IT July 17, 1998. International Patent Application No. PTC/IE99/00066, filed on July 15,1999, has been extended in the following countries: Australia, Canada, China, Europe, Japan, Mexico, New Zelanda, Norway, U.S.A. The International Preliminary Examination Report, issued at the end of the PCT procedure, has acknowledged the novelty of the claimsJapan: Patent Applications No. 2000-559833, filed on January 15, 2001.Mexico: Patent No. 000527, filed on January 15, 2001.Norway: Patent Applications No. 20010248, filed on January 15, 2001.
7) “Use of rubidium and in particular rubidium chloride as an antimaniac agent and stabilizer for mood swings”.
Priority date(s): IE April 19, 1999. International Patent Application No. PTC/IE00/0004, filed on April 17,2000, has been extended, within the terms foreseen by the international conventions, in the following countries: Canada, China, Europe, Japan, Mexico, New Zelanda, Norway, U.S.A. The International Preliminary Examination Report, issued at the end of the PCT procedure, has expressed a favourable opinion with regard to novelty, inventiveness and industrial applicability.
8) “TLP Peptides and DNA-sequences coding the same”.
Priority date(s): IT February 25, 2000. The International Patent Application No. PTC/E001/01857, filed on Februry 20,2001, has been extended, within the terms foreseen by the in ternational conventions, in the following countries: Australia, Brazil, Canada, China, Japan, North Corea, Russian Federation, South Corea, U.S.A. Europe, designating: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland Liechteinstein, Turkey, United Kingdom. The International Preliminary Examination has been concluded (IPER issued on May 21, 2002) with a positive opinion regard to novelty, inventiveness and industrial applicability of the claims concerning the cDNA of TLP, the peptide coded by the same and the relevant pharmaceutical compositions.
9) “Diphenyl ketoaldehyde derivatives with anti-HIV activity”.
Priority date(s): IT March 24, 2000. The International Patent Application No. PTC/EP01/03343, filed on March 23,2001, has been extended, within the terms foreseen by the international conventions, in the following countries: Australia, Brazil, Canada, China, Japan, Mexico, New Zelanda, Norway, Russian Federation, South Africa, U.S.A. Europe, designating the following countries: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland/Liechteinstein, Turkey, United Kingdom. The International Preliminary Examination Report, issued at the end of the PCT procedure, has acknowwledged the novelty of the invention.
10) “Compounds with anti-Rhinovirus activity”.
Italy: The Patent Application filed on June 9,2000 under No. MI2000A001288, has not been extended.
11) “Slow release” pharmaceutical compositions comprising lithium carbonate.
Priority Date(s): IT August 6, 2001.
Priority: IT/10.08.00/ITA MI001868 + IT/14.O2.01/MI000299. Designated states: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR.
The International Patent Application No. PTC/EP01/09054, filed on August 6,2001, and extended, within the term foreseen by the international conventions, in the following countries: Europe, designating the following countries: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland/Liechteinstein, Turkey, United Kingdom, and moreover in: “Euroasiatic Area”, designating the following countries: Armenia, Azerbaijan, Belarrus, Russian Federation, Kyrgyzstan, Kazakhstan, Maldava, Tajikistan, Turkmenistan.Australia, Brazil, Canada, China, Japan, U.S.A.On October 2, 2002, the IPER (International Preliminary Examination Report), has expressly acknowledged novelty, inventiveness and industrial applicability of all the five claims.
12) “TLP Antigen and diagnostic applications thereof”.
Priority Date (s): IT, June 29,2001.The International Patent Application No. PTC/EP02/07020, filed on June 25, 2002, has been published on January 9, 2003 under No. WO03/002591.The international preliminary examination concluded within October 29, 2003, while the national/regional started within December 29, 2003.
13) “Fusion Proteins containing TLP peptides”.
Priority Date (s): IT, November 30, 2001. The International Patent Application No. PTC/EP02/13470 has been filed on November 29, 2002.
14) “Compounds with anti-Rhinovirus activity”.
The Italian Patent Application (No. MI2002A000966), filed on May 8, 2002, extended within the priority year as PTC application.
Date (s): December 13, 2004. Application No./Patent No.: 03727431.3-2123-EP0304673. Date of filing: May 5, 2003. Priority: IT/08.05.02/ITA MI20020966. Designated states: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR.
15) “Pharmaceutical composition containing the association LevodopaCarbidopa”.
Italian Application filed on April 18, 2003.
16) “Pharmaceutical compositions containing interferon f or the treatment of Human Papilloma Virus Infections”.
Italian Application filed on April 18, 2003.
17) “Method of treating viral hepatitis by administration of liquid human α-interferon”
Issued on April 26, 2005 Patent 6884411 – US classes
Selected publications (over 500 articles in total)
- Recherches sur le mechanisme d’action d’un groupe de medicaments a activité antivirale (produits chetoaldéhydiques du diphényle et leur derivés): Facteurs qui interferent sur leur activité protectrice in vivo. (with F. Magrassi, P. Altucci et al.). III Internat. Congr. Of Chemotherapy – Stutgart, July 1963. Proceedings, pag. 783 (1964).
- Studies on the mechanism of antiviral activity of ketoaldehyde derivates of biphenyl. (with F. Magrassi, P. Altucci et al.) International “Symposium on non specific resistance to virus infection, Interferon and viral chemotherapy” Smolenice, September 1964. Chemotherapia 9, 341, 1964.
- Studies on the mechanism of antiviral activity of biphenyl ketoaldeydes. (with F. Magrassi, p. Altucci et al.) Proceedings of the Fourth Congress of the Hungarian Association of Microbiologists Akadémiai Kiado Budapest 1964, pag. 11.
- Properties of an avirulent influenza A virus variant derived from drug treated mice infected with PR8 virus. (with F. Magrassi, et al.) In “Antimicrobial Agent and Chemotherapy” pag 605 (1965).
- Properties of an avirulent influenza A virus variant derived from drug treated mice infected with PR8 virus. (with F. Magrassi, et al.) Arch. ges. Virusforsch, 18, 422, 1966.
- Effect of Streptovitacin A on replication of RNA virus (poliovirus). Proc. Soc. Exp. Biol. Med. 126, 535. 1967.
- Virus Specific, Labile, Nonvirion Antigen in Herpes Virus Infected Cells. (with A. B. Sabin) Proc. Natl. Acad. Sci. U.S. 65, 753, 1970.
- Increase in Preexisting Cellular Antigen Combining Groups al Different Times after Infection with Different Viruses. (with A. Sabin) Proc. Natl. Acad. Sci. U.S. 67, 731, 1970.
- Studies on the mechanism of antiviral activity of Ketoaldheide derivates of bifhenil. (with F. Magrassi et al.) Rev. roum. d’inframicobiol. 5, 275, 1968.
- Effect of two methisazone derivatives on herpes simplex virus replication. (with P. Mastroeni). VII Intern. Congress of Chemoterapy, August 1971 Avicenum, Czechoslovak Medical Press, Praga, pag. 273.
- Soluble Membrane Antigens of Lip and Cervical carcinomas: Reactivity with Antibody for Herpesvirus Nonvirion Antigens. (with A.C. Hollinshead) Science 179, 698, 1973.
- Apperance in Trypsinized Normal Cells of Reactivity with Antibody Presumably Specific for Malignant Cells. Proc. Nat Acad. Sci. USA 70, 325, 1973.
- Nonvirion Antigens Produced by Herpes Simplex Viruses I and 2. (with A. B. Sabin) Proc. Nat. Acad. Sci. USA, 70, 1032, 1973.
- Herpes Simplex and Herpes Genitalis Virus in Etiology of Some Human Cancers. (with A. B. Sabin) Proc. Nat. Acad. Sci. USA, A70, 3225, 1973.
- Studies of Tumor-specific and Herpes Virus Non virion Antigens. (with A. Hollinshead et al.) Cancer Res. 34, 1122, 1974.
- Characterization of herpesvirus non virion antigens: relation to squamous cell carcinomas.(with A. Hollinshead, W. Rawls e P. Chretien) In E. Kurstak and R. Morriset (ed) “Viral Immunodiagnosis”, Academic Press, New York, 1974.
- Soluble Membrane Antigens of Lip and Cervical carcinomas: Reactivity with Antibody for Herpesvirus Nonvirion Antigens. (with A.C. Hollinshead) Year Book of Cancer 1974.
- Analysis and Description of Procedures Used in the Study of the Relationship of Herpes Simplex “Nonvirion” Antigens to Certain Cancers. In C. de Thé, M. A. Epstein, H. zur Hansen (ed.) “Oncogenesis and Herpesviruses” I.A.R.C., Lyon 1975.
- Preliminary studies of nonvirion antigens associated with Herpes Simplex virus 1 and 2 (HSV-1- HSV-2) (with Accini R. et al.) Boll. Ist. Sieroter. Milanese 55, 120 1976
- Herpes Simplex virus nuclear non virion antigens detected by anticomplement immunofluorescence (with Giordano C. et al.) Tumori 62 (6) 609, 1976
- Herpes Simplex virus tumour associated antigens in cancer patients (with Di Gioia M. et al.) Tumori 62 (6) 615, 1976
- Cell-mediated immunity to Herpes Simplex virus types 1 and 2 antigens in leucoplakia and carcinoma in man. (with E. J. Shillitoe, T. Lehner) Oncology 33, 192, 1976.
- Detection of early antigens in nuclei of cells infected by cytomegalovirus, Herpes Simplex type 1 and 2 by anticomplement immunofluorescence and blocking assay to demonstrate their specifity.(with G. Giraldo, E. Beth, U. Hammerling, F.M. Kourilsky)Int. J. Cancer 19, 17, 1977.
- Enzyme Linked Immunosorbent Assay for Herpes Simplex Virus Tumor-associated Antigen. (with R. Cocchiara et al.) Cancer 45, 938, 1980.
- An Immune Enzymatic Assay for Purified Tumor Associated antigen of Herpes Simplex Virus.(in coll.) Cellular and Molecular Biology 25, 329, 1980.
- Purification of Herpes Virus Tumor Associated Antigen from Human Kidney Carcinoma. (with R. Cocchiara et al.) Cancer 46, 1594, 1980.
- Foreword of the proceedings of the First International Congress of Viral Oncology The role of Virus in Human Cancer, vol. 1 Elsevier, North Holland, 1980.
- Herpes Simplex Virus Tumor Associated Antigen (HSV-TAA) Detected by the Enzyme-Linked Immunosorbent Assay (ELISA). in The Role of Viruses in Human Cancer, vol. 1, Giraldo e Beth Editori, Elsevier North Holland inc., pag. 108, 1980.
- Il TAF test: un nuovo metodo per la diagnosi di alcuni tumori. Rivista Medica della Svizzera Italiana 45, 245, 1980
- Monoclonal Antibodies to Herpes Simplex Virus Tumor Associated Antigen. (with A. Karpas e T. Wheeler) International Workshop on Herpesviruses Soc. Edizioni Esculapio, Bologna 1981, pag. 232.
- Circulating Immunocomplexes (CIC) in Sera of Patients with Herpes Simplex Virus (HSV) – Associated carcinomas. (in coll.) International Workshop on Herpesviruses Soc. Edizioni Esculapio, Bologna 1981, pag. 236.
- Traitment de la herpetique avec le metiseprinol. Aspect clinique et histologique (with Gorgone G., Cavallaro N., Scaletta S., Carnazza S., Ricci M., Gala Trinchera G., Cordaro S.) Bull. Soc. Belge Ophtal. 192 113-123 1981
- Perspectives and limits of an immunoenzymatic assay (ELISA) for Herpes Simplex Virus (HSV) Tumor-Associated Antigen (TAA). Cancer Detection and Prevenction 4, 47, 1981.
- An immunoenzymatic assay for herpes simplex virus tumour associated antigen in gynaecological oncology (with Magli G., Scimone C., Flaminio G., D’Alessandro G., Mascolo A., Magli R., Saladino I.) Eur. J. Gynaec. Oncol. 1982 ISSN: 0392.2936.III.2
- Further Studies on an Immunoenzymatic Assay for Heres Simplex Virus-Tumor Associated Antigen. (in coll.) Clin. Immunol. Immunopath.. 25, 126, 1982.
- Human tumor antigens inducing in vivo delayed hypersensitivity and in vitro mitogenic activity. (with A. Pederzini et al.) Oncology 40, 248, 1983.
- As above Immunomodulation amd Therapy in Cancer (with Pedercini A. et al.) ed. H.H. Fuderberg, P. Pontiggia, C. Ogler, Acta Medica edit. Congressi 1983, pag. 307
- Virological Investigation of Young Children with Acute Respiratory Syndrome Associated with Respiratory Synctyal Virus (RSV). (in coll.) in Medical Virology II, Editor L.M. de La Maza, E.M.. Peterson Elseiver Biomedical, 1983, p. 402.
- Quantitative Determination of Human CMV IgG Antibodies by solid phase enzyme immunoassay: comparison with CF test. (in coll.) in Medical Virology II – Editor L.M. de La Maza, E.M.. Peterson Elseiver Biomedical, 1983, p.392.
- Correlation between immune complexes and Herpes Simplex Virus (HSV) Tumor Associated Antigen (TAA) in Human Cancer Sera. (with others) Cellular and molecular biology 29, 394, 1983.
- The role of herpes simplex virus in the neoplastic pathologies and diagnostic markers. J. Exp. Clin. Cancer Res. 4 (2),213, 1985.
- Serological and Virological Investigations of Young Children with Acute respiratory Syndrome Associated with Respiratory Syncytial Virus. Diagnostic Microbiology and Infection Disease 3 (1), 81, 1985.
- The pathogenesis of malignant tumors X Dies Italico-Iugoslavici Medicinae destinati, Lugnano, 1985
- Screening haemodialysis patients for infection with human immune deficiency virus (HIV). Journal of Infection 14, 1987, pag. 229.
- Absence of risk of human immunodeficiency virus (HIV) infection in recipients of hepatitis B vaccine. Eur. J. Epidem. 3, 1987, pag. 323.
- Viruses and immunodeficiences. “Regulation of Mammalian Cell Growth”, Capri 27-9/2-10-87, pag. VIR 9, Ciba-Geigy.
- Monoclonal antibody for tumor associated antigens induced by Herpes Simplex Virus. Advances in Management of Malignancies, Proceedings of an international congress, Ascoli Piceno, 3/6-5-1988.
- Laboratory methods for diagnosis of AIDS. Significance of sierological markers (with others) Giornale italiano di patologia clinica 3 (6) 1988, pag. 393
- Search for tumour antigens to be used for active specific immunotherapy. Abstract book of the 2nd Internationl Congress “Advance in Management of Malignannces, Ascoli Piceno 28/5-1/6/1990 pag. 36
- Histochemistry and Immunolohistochemistry in the diagnosis of prostatic carcinoma (with others) Abstract book of the 2nd International Congress “Advances in Management of Malignancies”, Ascoli Pisceno, 28/5-1/6-1990, pag. 93
- Epidemiological, serological, evolution aspects of HIV infection and related malignancies within Naples area (Jan ’86-Dec. ’89). Abstract book of the 2nd International Congress “Advances in Management of Malignancies”, Ascoli Pisceno, 28/5-1/6-1990, pag. 19.
- Methoden in vitro als tierversuchersatz bei immunologishen studien. in AA.VV. “Artze fur Die Abschaffung der Tierversuche” Bern 1990, p. 77 (German); p. 167 (French); p. 255 (Italian).
- Neutralization test and antibody titers in AIDS (with Valguarmera G. et al.) Clinica Europea 30 (2) June 1991
- HIV Infection and Serological Response (with Esposito C. et al.) Biochimica clinica 15, 1991
- Seroepidemiologic patten of HCV infection in Campania during the first six months 1992. (with C. Esposito et al..) Abstract, Journal of Hepatology supplement 1 to vol, 17, 5028, 1992
- Screening of HTLV-1 infection drug addicts from Campania region. Advances in Management of Malignancies Pisa, 6/10-12, 1993, pag.33 BIOS Ed.
- Lung carcinoma histopatholocic approaches for a prognostic valuation (with others) Advances in Management of Malignancies Pisa 6/10- 12/1995 pag. 237 BIOS ed.
- Antigenic regions of tumour liberated protein complexes and antibodies against the same (with. Marshak DR et al) In Third International Congress. Advances in Management of Malignancies. Pisa, Italy 6/10 December 1993 Biomed & Pharmacother 47:237
- Vom Anthropozentrismus zur Antivisektion: Tierschtz heute und Jurassic Park. Proceedings of International Medical Congress, Lugano 20-11-93. LIMAV, pag. 195 Ed. ASTRA/AG STG March 1995.
- Passive immunotherapy in AIDS patients Rivista Italiana di Ricerche Mediche e Chirurigiche Anno III vol. 3 n. 3 September 1995 pag. 11
- Anti-TLP antibodies in lung cancer patients. (with C. Esposito et al.) Internal Medicine Clinical and Laboratory 5 191-194, 1997.
- The Genoma Project: Ethical implications in oncology. In: Internal Medicine Clinical and Laboratory 6 67-72, 1998
- Immunoistochemical characterization of tumour liberated particles (TLP) expression pattern in
lung cancer. (with Giordano A. et al.) Anticancer Res 18:2365-2370, 1998
- Los derechos de los animales Actas Congreso medico international LIMAV Madrid Mayo 1997 ARTA STG enero 1998
- Effect of Bergarital on virus replication Rivista Italiana di ricerche Mediche e Chirurgiche Editrice Doctor’s Anno VI n. 2/4 aprile/dicembre 1998
- Neoangiogenesis and prognosis in lung cencer (with A. Perna et al.) Internal Medicine Clinical and Laboratory 7 111-113, 1999
- Tumor liberated protein (TLP). Its potential for diagnosis and therapy. Anticancer Res 19: 1755-1758, 1999
- Immunità da Herpes Simplex Virus (HSV) (with others) Proceedings of International Workshop on Viruses Immunities and Diseases, Naples, October 1999
- AIMS and Perspectives for Tumor Liberated Protein (TLP) Proceding of the Joint International Cancer Conference “New Dimension in Cancer Biology on Therapy” Edition H. Ozer, K. Khalili, G.C. Giordano
- As above Riv It Ric. Med Chir 7:43-46 1999
- Vom Tumor freigesetze Proteine: Neuer Wendepunkt fur Diagnose und Therapie ohne Notwendigkeit von Tierversuchen. Humanmedizin ohne Tierversuche: Die Artze haben das wort. Berlin Mai 1999, ASTRA – AG STG pagg. 67-74
- Overview of the Lung Tumor Liberated Protein (TLP): Characterization of Genetic Immunologic Profile Internal Medicine Clinical and Laboratory 8 33-38, 2000
- Immunochemical evaluation of endothelal damage by angioinvasivity. (with Perna A, et al.) Int J. Clin Invest 9 :31-33, 2001
- Production and characterization of anti-TLP derived peptide RTNKZEASIC) monoclonal antibodies. (with Esposito C. et al.) Int Med 9:55-61, 2001
- Characterization of a Fragment Containing a Putative TLP DNA Sequence. Anticancer Research, 22: 2693-6, 2002
- UCV genotypes and antibodies reactivity what’s relation? Journal of Hepathology Suppl. n.1, Vol.30, 1999 pag.209. (with C. Esposito, F. Morelli, N. Cuomo, A. Di Spirito)
- Evaluation of a new test for the determination of the genotypes HCV JournaI or Clinical Virology, 22/2: 174, 2002
- Hepatopaty and oxidative stress: clinical study on the efficacy of the depatox Int.. Clin. Invest. 1 : 15 -18, 2003
- Determination of the HBV polymerasis gene mutation in HBV ECA patients treated and naive. (with Esposito C. et al.) Journal of Clinical Virology suppl. August 12 27 2003,
- Progress and new hope in the fight against cancer: novel developments in early detection of lung cancer.(with C. Esposito), in InternaI Medicine 10 7-11, 2002
- Extracorporeal Whole Body Hyperthermia in the treatment of C Hepatitis.IJCI Int.. Clin. Invest. XII 1 – 4, 9 -10, 2004
- Stem cells. State of art and perspectives. Biomedicine and Pharmacotherapy 58 463-464, 2004
- Early diagnosis of lung cancer by detection of Tumour Liberated Protein Journal of Cellular Physiol 203 1-5, 2005
- Biomolecular Markers of breast Cancer (with A. Nicolini and A. Carpi). Frontiers in Bioscience
- (United States), 2006, 11 pag. 1818-43
- New hope in early detection of NSCL cancer
- New Research Communications on Tumor Markers
- Nova Publisher, New York, N.Y., in press
- TLP in Screening, early diagnosis and follow up of NSCLC Int. J. Clin. Invest. 3-4; 75 – 82, 2006
- Tumor Liberated Protein from Lung Concer and Perspectives for Immunotherapy Journal of Cellular Physiology, 221: 26-30, 2009.
- Consideration on Epidemic Flu Viruses. (Int. J. Clin. Invest., 29 (1-2): 2009.
- Preface to lose weight without misteries will the Progressive Swing Diet by Michele D’Antoni, iUniverse, Inc. New York bloomingtore, 2009. Not any longer sick children: prevention of viral diseases in pregnancy. WABT Congress, Budapest Dec 10-12, 2010 – Book for Life Foundation.
- Giulio Tarro U.S. National Library of Medicine – National Institute of Health – National Center for Biotechnology Information, Pub Med EN/IT. Chiron, Settembre 2010.
- Emerging Viral Agent at Risk in Global Health Approciates to Early Diagnosis and Prompt Therapy, con C. Esposito. BIOCOMP 11: July 18-21, 2011, Las Vegas, Nevada (USA) CS REA Press.
- Lung Cancer Proteomics: Recent Advances in Biomarkers Discovery, con P. Indovina, E. Marcelli, P. Maranta. International Journal of Proteomics Vol. 2011 Article ID 726869, 7 pages.
- Mass – spectrometry based proteomic the road to lung cancer biomarker discovering Predictive, Preventive and Personalized Medicine (PPPM) con P. Indovina, E. Marcelli, F. Pentimalli, P. Tanganello ed A. Giordano. Mass – spectrometry Reviews, Springer SMA Journal: PPPM in Cancer 2012.
- VirusSphere, Doctor Mag, The Medical Web Magazine.
- Peptide Search in the Tumor Liberated Protein (TLP) from Non Small Cell Lung (NSCL) Cancer.
BIT’s 4th Annual World Congress of BioSoft, March 23-25, 2012, Beijing China.
- Search in the Tumor Liberated Protein (TLP) for Specific Peptides of Non Small Cell Lung (NSCL) Cancer. BIOCOMP 12: July 16-19, 2012, Las Vegas, Nevada (USA) CS REA Press.
- Tracking the 2009 H1N1 Influenza Virus in the Italian Region Campania, con C. Esposito, A. Di Spirito et al. Journal of Cellular Physiology Vol 227: 2813-2817, July 2012.
- TLP Sequenced and Studied for its Functions with Targets Diagnostic and Therapeutic, G. Tarro. Advanced Studies in Biology, Vol 5, n. 5, 191-198, 2013 HIKARI Ltd.
- From Sequence of Tumor Liberated Protein (TLP) to Function and Potential Targets for Diagnosis and Therapy, G. Tarro. BIOCOMP 11: July 2013, Las Vegas, Nevada (USA) CS REA Press
- Origin of the Viruses and their Evolutionary History, G. Tarro. Advanced Studies in Biology, Vol 5, n. 9, 423-430, 2013 HIKARI Ltd.
- New Development on Tumor associated Antigen with specific target toward Lung Cancer, G. Tarro. International Journal of Research in Medical and Health Sciences, Vol. 4, Issue 2, ISSN 2307-2083, 29 June 2014.
- Viral Latency, Molecular Pathogenesis and Malignancy, G. Tarro. Global Journal of Science Frontier Research © Vol. XIV, Issue III, Vers. I, 2014.
- L’epidemia da virus Ebola. www.assis.it , 27 agosto 2014.
- Micoplasmi e micoplasmosi: 20 anni dopo, G. Tarro, P. Altucci. Estratto da Il Policlinico – sez. Pratica, vol. 121 – N. 9, Settembre 2014, pagg. 229-245.
- Ruolo dell’Etio-patogenesi in Medicina Interna. P. Altucci e G. Tarro. Policlinico Sez. Med. 2014; 121: 61-81, doi. 107353/polimed.2014.121.
- Migratory Phenomenons, Biothics and Vaccinations Advances in Microbiology (accepted Sept 2015) in cod 8 I. F. = 0,94.
- Bergamot (Citrus bergamia Risso and Poitean) Essential Oil,. Peel and Juice: a Review of Antimicrobiol, Anti-inflemmatory and other Medicinal Properties with Paolo Morabito et al. Clin. Microb. Rev. (accepted Sept 2015) in c.d.p. I.F. = 17.
- Lights and shadows of vaccinations. J of Vaccine Research and Development in c.d.p.
- Exegesis of Sabin poliovaccine in terms of medical science. J of Vaccine Research and Development in press.
- Le ombre dell’immunoprofilassi. Bollettino Ordine M.C. e O. Napoli, anno 85 n. 7 pagg. 12-13, dicembre 2015.
- Anti-Rhinovirus Activity of Ethyl1 4-(3-(2-(3-Methylisoxazol-5-Y1) Etthoxy) Propoxy) Benzoate (EMEB). Pharma Anal Acta 2016, 7:469. Doi: 10.4172/2153-2435.1000469.
- Oncologic Virology, Idelson, Naples 1979
- Pathology of AIDS, Mapograf, Vibo Valentia 1991
- With cancer one can live, Mapograf, Vibo Valentia 1992
- AIDS: what we can do what we must know, Mapograf, Vibo Valentia 1994
- Pocket File Research Collection, Doctor’s, Naples 1997, 6th edit., 2003
- To Prevent Is To Win, Italia Sud, Rome 1998
- Bioethics and Culture of Prevention, Apẻiron, Bologna 2001
- Health without borders, Imago Media, Edition Piedimonte Matese, December 2004
- Health without borders, number 2, Rubbettino Editore, Soveria Mannelli 2007
- Safety no limits, Cassa Risparmio San Miniato 2008
- Health without borders, 4. Ed. Helicon Arezzo 2009.
- Medicina e Recenti Miracoli, Totus tuus edit. 2010.
- Sanità senza frontiere 5, ed. Chiron, 2012.
- Campania, terra di veleni, Denaro libri, 2012.
- La medicina è la Vita. Essere medico nell’era della Globalizzazione
Ilmiolibro.it, editoriale l’Espresso. Libri per Amici. ISBN: 978-88-91050-73-1 Copyright 2013
- La medicina è la Vita. Essere medico nell’era della Globalizzazione
Ilmiolibro.it, editoriale l’Espresso. Libri per Amici. ISBN: 978-88-91063-38-0, anno 2013
- Il cancro dovrebbe essere solo un segno zodiacale. Tutti insieme contro il cancro!
Edito dalla Fondazione de Beaumont Bonelli per le ricerche sul cancro – ONLUS. 31 Ottobre 2013
- Il cancro dovrebbe essere solo un segno zodiacale. Tutti insieme contro il cancro!
Edito dalla Fondazione de Beaumont Bonelli per le ricerche sul cancro – ONLUS. Marzo 2015
- Sanità senza frontiere n 6
- Curriculum vitae et studiorum
1) Effect of Various DNA Inhibitors on Synthesis of CF Antigens in Cell Cultures Infected with HSV. Intern. Congress of Chemoterapy, Tokio, August 1969.
2) Effect of DNA Inhibitors on Synthesis of Herpes Simplex Virus Antigens. (with P. Mastroeni). X Internat. Congress of Microbiol., Mexico City, August 1970.
3) Immunofluorescence of Virion and “Non Virion” Herpes Simplex Virus Antigens. (with G. Carrera). As above.
4) Current and future studies on Non Virion Herpes Antigens. VI Meeting European Tumor Virus Group Bad Vjmpfen, Heidelberg, April 1971.
5) Effect of two methisazone derivatives on herpes simplex virus replication. (with P. Mastroeni). VII Intern, Congress of Chemoth. Prague, August 1971.
6) Complement fixing nonvirion antigens in cells infected with different strains of herpes virus. VII Meeting of the European Tumor Virus Group (E.T.V.G.) Zierikzee. The Nederlands Sept. 25-27, 1972.
7) Complement fixing reactivity of trypsin treated normal human cells with immunoglobulin against transformed and virus infected cells VII Meeting E.T.V.G., as above.
8) Herpes simplex and genital virus Non-virion antigens: their use for determining the role of these viruses in etiology of some human cancers. (with A. Sabin). Annual Meeting of NationalAcademy of Sciences. 1973-4-23 WashingtonD.C. (USA).
9) Result of recent studies on the role of the virus of Herpes simplex and Herpes genital in certain human cancers. (with A. Sabin). XIV European Symposium of Poliomemyelitis and other virus deseases. 1973-6-13 Ankara (Turkey).
10) Presence of Antibody for Herpes Non-virion Antigens in Sera of Cancer Patients. In Proceedings of the II Intern. Symposium on Cancer Detection and Prevention, Bologna. Excerpta Med. 275, 120, 1973.
11) Separation and analysis of herpesvirus genetic markers. Human Tumor Virus Meeting on the Herpesviruses Aug. 17-20, 1973. Cold Spring Harbor, New York.
12) Further studies on antibodies for herpesvirus nonvirion antigens and presence of herpesvirus genetic markers in cancer patients. The Eighth Meeting of the European Tumor Virus Group, Aviemore, Scotland ApriI2-5, 1974.
13) Antibodies for herpesvirus nonvirion antigens and herpes virus genetic markers in cancer patients. 2nd Scientific Meeting Group of Cooperation in Immunol. (G.C.I.). S. Gimignano 31 May. 1 June 1974.
14) Characterization of HSV nonvirion antigens: relation to squamous cell carcinomas.
Il Internat. Conference on Comparative Virology. Mt. Gabriel, Canada, Aug. 22-24, 1974.
15) Herpes Simplex Viruses l and 2 “Nonvirion» Antigens and Specific Antibodies in Immune Animals and Cancer Patients. II Int. Symp. on Oncogenesis and Herpesviruses. Nủrnberg October 14-16 1974,
16) Antibodies for Herpesvirus nonvirion antigens and herpesvirus genetic markers in cancer patients.XI Int. Cancer Congress. Firenze October 20-26 1974.
17) Nuclear “nonvirion” and soluble membrane antigens of herpes simplex virus: their relation to some human tumours. (with G. G. Giordano et al.). IX Meeting E.T.V.G. Mariehamn, Finland May 26-28 1975.
18) Herpes simplex virus antigens and their relation to some human cancers. (with G. Carrera). III Int. Congress for Virology. Madrid, Spain Sept. 10-12 1975.
19) Radioimmunological studies on nonvirion antigens induced by herpes simplex virus. (with R. Accinni and A. Bartorelli). Symp. on Herpesviruses Liblice. Castle, Czechoslovakia, June 1976.
20) Biochemical and Radioimmunological studies on nonvirion antigens of herpes simplex virus. (with R. Accinni et al.). III Intern. Symp. on Detection and Prevention of Cancer, New York, April 1976.
21) Purification of Herpes simplex virus (HSV l) by isoelectric focusing. (with R. Cocchiara et al.). Xth Meeting E.T.V.G. Grindelwald, Switzerland, Oct. 3-7 1976.
22) Nuclear «nonvirion” antigens of herpes simplex virus and their relation to some Human tumours. (with G. G. Giordano et al.). III Intern. Symp. on Detection and Prevention of Cancer, New York April 1976.
23) Purification of herpes simplex virus (HSV-1) by isolelectric focusing. (with R. Cocchiara et al.). III Intern. Symposium on Cancer Immunotheraphy, Bucharest 1-2 Sept. 1977.
24) Purification of herpes simplex virus tumor associated antigen (s) from infected cells and from human carcinomas (with R. Cocchiara et al.). 11 th Meeting European Tumor Virus Group, Balatonfured (Hungary) May 8-12 1978.
25) Purification and Characterization of an Antigen Extracted from Herpes Simplex Virus (HSV) Infected or Transformed Cells and from Certain Human Tumours. Herpes Virus Workshop, Cambridge (England). August 1978.
26) Tryptic Peptide Analysis of Purified Herpes Simplex Virus (HSV) Tumour Associated Antigen (TAA) from Different Sources. (with R. Cocchiara et al.). Fourth Intern. Congress for Virology. The Hague, The Netherlands Aug. 30 -Sept. 6, 1978.
27) Enzylme-Iinked immunosorbent assay for herpes simplex virus tumours associated antigen. (with G. Flaminio et al.). Proc. XII International of Cancer Congress, Buenos Aires, Oct. 1978, Mesas de Trabajo.
28) The importance of ELISA in screening early antibody for HSV cervix uteri tumors associated antigens. (with G. Magli et al.). I Symp. It. Soc. of Gynaecologic Oncology, Rome, Dec. 1-2 1978.
29) Herpes simplex virus Tumor Associated Antigen (HSV-TAA) detected by the Enzyme-Linked Immunosorbent Assay (ELISA), VII Nat. Meeting of. Group. Coop. in Immunol., Cortona, June 15-17 1979.
30) HSV-induced nonvirion antigen in GPK cells multiplying in spinner flasks. (with G. Flaminio et al.). IV Herpesvirus Workshop, ColdSpringHarbor Laboratory (New York) , 28-8/2-9-1979.
31) Immunoenzymatic Assay for the screening of HSV-TAA in certain human tumours. 12° European Meeting Tumour Virus Group. SPA, Belgium, 10/14 Sept. 1979:
32) Herpes Simplex Virus induced Tumour Associated Antigen. As above
33) Perspectives and limits of an immunoenzymatic assay for HSV-TAA. lntemational Symposium on Detection and Prevention of Cancer, London, July 26/31, 80.
34) Purification and characterization of type 2 HSV-TAA. As above
35) Monoclonal antibodies to Herpes Simplex Virus Tumor Associated Antigen (with Karpas e T. Wheeler). lnternational Workshop on herpesviruses. Bologna (Italy). July 1980.
36) Circulating Immunocomplexes (C1C) in Sera of Patients with Herpes Simplex Virus (HSV) – Associated Carcinomas. As above.
37) Circulating Immunocomplexes (CIC) in sera of Patients with Herpes Simples Virus (HSV) – Associated Carcinomas. VI Meeting of the European Association for Cancer Research; Budapest – Hungary, 12/15-10/1981.
38) Human Tumor Antigens Inducing in Vivo Delaved Hypersensitivity and in vitro Mitogenic Activity. 13° International Cancer Congress. Seattle, Washington, USA, 8/15-9-1982.
39) Herpes Simplex Virus and Human Tumors. 14° Meeting of the European Tumor Virus Oroup; Druzhba-VarnaBulgaria; 24/28-10-1982.
40) Virological Investigations of Young Children with Acute Respiratory Syndrome Associated with Respiratory Syncytial Virus (RSV). The Int. Symposium on Medical Virology. Disneyland Hotel, Anaheim (Los Angeles) California, 2/4-12-1982.
41) Quantitative Determination of Human CMV IgG Antibodies by Solid Phase Enzyme Immunoassay (ELISA): Comparison with CF test. As above
42) HSV-TAF purified by column and analytical isoelectric focusing. 6th lnternational Symposium on Prevention and Detection of Cancer, Wien. 26/ 29 Nov. 1984.
43) Safety of Hepatitis B vaccine: lack of evidence of AlDS agents transmission; First international meeting of AVIS: ” AIDS: Diagnosis, prevention and therapy, advances and prospectives in virus research”, 1985-12-6, Naples.
44) Prevalence of antibodies to AIDS associated retroviruses on the Naples area; as above
45) HBV as possible cofactor for AIDS. Symposium Praesidium. “XI Dies ItaJico-Jugoslavici Medicinae Destinati, 1986-5-30, Dubrovnik, Jugoslavia.
46) Viruses and Immunodeficiences. Inter. Symposium on “Regulation of Mammallian CeII, 1987-9-27, Capri (NA).
47) Monoclonal antibody for tumor associated antigens induced by Herpes Simplex Virus. International Congress Advances in Management of Malignancies”, 1988-5-3, Ascoli Piceno.
48) Behaviour of beta2m in some oncoemopathies. XV World Congress of Anatomic and Clinical Pathology, 1989-5-16 Firenze.
49) Epidemiological, serological, evolution aspects of HIV infection and related malignancies within Naples area (Jan ’86 – Dec. ’89). II Intemational Congress Advances in Management or Malignancies”, 1990-5-28, Ascoli Piceno.
50) Search for tumor antigens to be used for active specific immunotherapy. As above
51) Histochemistry and Immunohistochemistry in the diagnosis of prostatic carcinoma. As above
52) IgE Ferritine: Markers of relapse in Hodgkin disease. As above
53) Naples Group C Centre for Anonimous HIV Screening. VI International Conrerence on AIDS, 1990-6-2, San Francisco (USA).
54) In vitro toxicity and immunogenicity of seven endodontic materials. Meeting of Int. Assoc. of Dental Research I.A.D.R.), 1992-7-1, Glasgow, Scotland.
55) Opportunistic viraI infection in 124 patients recognised by celI culture virus isolation. VIII International Conference on AIDS, 1992-7-19, Amsterdam.
56) Seroepidemiologic pattern of HCV infection in Campania during the first six months of 1992. Third International Conference on Current Trends in ChronicalIy Evolving Virai Hepatitis, 1992-10-4, Pisa.
57) A fast and sensitive technique for cytomegalovirus isolation from liquid by celI culture. 6th European Congress or Clinical Microbiology and Infectious Disease, 1993-3-28, Seville (Spain).
58) Importance of p24 antigen in the detection of HIV infection. IX International Conference on AIDS, 1993-6-6, Berlin.
59) Ratio CD5/CD8 and percentage in HIV infected people. H1V infection in drug addicts correlated to HBV and HCV. As above
60) Antigenic Regions of Tumor Liberated Protein Complexes and Antibodies Against the Same.
Advances in Management of Malignancies, 1993-12-6/10, Pisa.
61) Lung Carcinoma Histopathologic Approaches for a Prognostic Evaluation. As above
62) Screening of HTLV-I in Drug Addicts from Campania Region. As above
63) Ratio CD5/CD8 in HIV infected people: fourth European Conference of Clinical Aspects and Treatment of HIV lnfection, 1994-3-16 Milano.
64) Interactions of human immunodeficiency virus and the hepatotropic viruses in drug addicts. lnternational Congress Biotech ’94 on AIDS, 1994-4-10 Firenze.
65) Ethics and Med. Legal problems in HIV Seropositivity communication. Tenth International Conference on AIDS, 1994-8-7, Yokohama (Japan).
66) Hepatitis viruses in HIV infected intravenous drug users. Fourth International Conference on Current Trends in Chronical EvoIving ViraI Hepatitis, 1995-3-30, Perugia.
67) Coinfection of Hepatitis viruses and HIV in intravenous drug users. Third International Conference on AIDS in Asia and the Pacific. The Fifth National AIDS Seminar in Thailand, 1995-9-17/21 , Chiang Mai (Thailand).
68) HTLV 1/2 and H1V infection in drug addicts (DA). 3rd Conference on Retroviruses and Opportunistic lnfections, 1996-1-28/31 Washington, DC (USA).
69) Relationship between HCV genotypes and antibody reactivity. Xth International Congress of Virology, 1996-8-11/16, Gerusalemme (Israele).
70) Further study on HCV genotypes of Naples province. 6th International Conference on Laboratory Medicine, 1996-9-13/16, Capri (NA).
71) Angiogenesis and vasculoinvasion in the colon adenocarcinoma: histopathologic approach. “Development cell differentiation and cancer”, 1996-9-28/10-2, Pisa
72) Elisa to detect anti-TLP (tumor liberated protein) antibody from lung cancer human sera. Comunicazione. Advances in Management or Malignancies, 1996-11-25/27, Pisa.
73) Development of TLP for Cancer First Joint International Conference “Gene Targets ror Cancer Treatment”, 1997-6-3/6, Capri (NA).
74) What correlation between HIV RNA and HCV RNA coinfection. Abstract (in coll.).
Inaugural Meeting or the European Society for Clinical Virology “Progress in Clinical Virology III”, 1997-9- 7/10, Bologna.
75) Utility or HIV-RNA as progression Marker in HIV infection, 4th International Congress on AIDS in Asia and the Paciflc, 1997 -I0- 25/29, Manila (Philiippines).
76) Decrease of HIV -RNA viral load below 200 copies/mi relates to basai viral load after combination therapy. 12th World AIDS Conference, Geneva (Switzerland) June 28- July 3, 1998.
77) Overview of the Lung Tumor Liberated Protein (TLP): Characterization of the Genetic Immunologic Profile. Biomedicine & pharmacotherapy 52 (7/8) :338, 1998.
78) Aims and perspectives for TLP. New Dimensions in Cancer Biology and Therapy. The 2nd Joint Intemational Conference, III session ViraI Etiology, Capri, Sept. 1998.
79) Relation between viraI load and different T cell population counts in HIV infection. AIDS and Related Sindroms . XII National Meeting. Genova 22/25-11-1998.
80) HCV Genotypes and Antibodies Reactivity: what’s relation? 34th Annual Meeting of the European Association for Study of the Liver. Napoli, 8-12 April 1999
81) Tumor Liberated Protein (TLP): its Potential for Diagnosis. IFCC-WorldLab ’99 Congress – Firenze, June 1999.
82) Evaluation of a new method of HCV RNA Real Time. International Workshop on Viruses Immunity and Disease, Napoli October 1999.
83) Further Evaluation of HAART Efficacy by the Ultrasensitive PCR Method for the Quantitation of HIV-I RNA in Human-Plasma. Seventh European Conference on Clinical Aspects and Treatment of HIV Infection. 10-23/27-1999, Lisboa (Portugal).
84) EI and E2 antibodies in HCV Chronic Hepatitis. Virology Meeting of Three Society, Stockolm Feb. 3-5, 2000.
85) Interleukin 2 production in Chronic HCV Infection: what correlation? Virology Meeting of Three Society, Stockolm Feb. 3-5, 2000.
86) Immunohistochemical evaluation of endothelial damage by angioinvasivity. Biomedicine & Pharmacotherapy, voI 54 n. 8-9 October 2000, page 445.
87) Monoclonal antibody to Tumor Liberated Protein (TLP): Serological and Immunohisto-chemical studies. Biomedicine & Pharmaco-therapy voI54 n. 8-9 October 2000, page 463.
88) Characterization of fragment containing a putative TLP cDNA sequence. Biomedicine & Pharmacotherapy voI 54 n. 8-9 October 2000, 463-464.
89) Production and characterization o[ anti-TLP-derived peptide (RTNKEASIC) monoclonal antibodies. Biomedicine & Pharmacotherapy voI 54 n. 8-9 October 2000, page 464.
90) No evidence of pig endogenous retrovirus infection in human susceptible cell lines in vitro exposed to human plasma perfused in bioartificial liver: preliminary results. II Int. Workshop on Immunity and viruses, 22-24, Feb.2001, Napoli page 55.
91) TTV Antibodies in patients with ECA HCV correlated Il Int. Workshop on Immunity and Viruses, 22-24 Feb. 2001, Napoli page 66.
92) Increasing HIV Incidence in Women, Proc. General Assembly United Nations, New York June 2001.
93) Evaluation of a new test for the determination of the HCV genotypes. 5th Annual Meeting ESCV, 2-5 Sept 2001 Lahti, Finland.
94) Determination or HBV polymerasis gene mutations in HBV ECA patients treated and naive. VII International Conference on Current Trends in Chronically Evolving ViraI Hepatitis, Sept. 23-25, 2001. Florence, Italy.
95) HCV-RNA ViraI load and HCV genotype: what correlation? VII Intern. Conference Current Trends in Clinically Evolving ViraI Hepatitis, Sept. 23-25,2001,Florence, Italy.
96) HIV protease and reverse transcriptase mutation identification.(with C. Esposito. N. Cuomo. F. Morelli,A. Di Spirito. M. lannece. P. Rosario. R. Pempinello.). The World of Microbs. Congress of The lnternational Union of Microbiological Societies (IUMS), Paris (France). 27/7-1/8/2002.
97) Progress and new hope in the fight against cancer: novel developments in early detection of lung cancer. Biomed Pharmacother 56:359-60. 2002.
98) “HIV mutation study during antiretroviral treatment” Winter Meeting – SPV /ESCV Joint Meeting of the Sociedade Portuguesa de Virologie and the European Society for Clinical Virology. Estoril (Portugal). 9-111112003, ESCV News letter, 13 June 2003. page 67.
99) The threat of Bioterrorism 3rd International Workshop on Immunology and Infectious Diseases. Infectious diseases from genetic implications to clinical aspects Napoli 8-10 June 2004.
100) Antiretroviral Treatment and HIV-l Mutation. Second European Congress of Virology Eurovirology 2004, Madrid, Spain, September 5-9 2004
101) Tumor Liberated Protein from Cancer and Perspectives for Immunotherapy. BIT Life Sciences 2° Annual World Vaccine Congress – Beijing, March 2010
102) AntiTLP (tumor Liberated Protein) Antibodies for Lung Cancer Cells and Identification of Whole Sequence of TLP. Search for the Cell Gene.
103) Theme: The Future of Global Vaccines. Beijing, March 2011.
104) Tumor Liberated Protein and Peptide Search for the Cell Gene and its Whole Sequence Theme: New Leaders in Protein and Peptide Science. Beijing, March 2011.
105) Antibodies against Non Small Lung Cancer Cells and their Role in Diagnosis and Immunotherapy of Lung Cancer. Theme: Discovery, Partnering to Market. Beijing, March 2011.
106) Fragments of Tumor Liberated Protein from Lung Cancer to Stimulate Immune Response to Attack Existing Tumors. Theme: Collaborative Actions against Cancer. Dalian (China), May 2011.
107) Emerging Viral Agents at Risk in Global Health Approches to Early Diagnosis and Prompt. Theme: Computational Biology. Las Vegas (USA), July 2011.
108) Tracking the 2009 H1N1 influenza virus in the Italian region Campania. PubMed 21928341.
109) Peptide Search in the Tumor Liberated Protein (TLP) from Non Small Cell Lung (NSCL) Cancer. BIT’s 4° Annual World Congress of Biosoft, Beijing, March 2012.
110) Tumor Liberated Protein (TLP) from lung cancer and perspectives for immunotherapy. OMICS Computer Aided Drug Disegn & Qsar. Chicago, October 2012.
111) Tumor Liberated Protein (TLP) and human corine in lung cancer cells: Homology or different isoforms in the sequence at the cytoplasmic surface. OMICS Computer Aided Drug Disegn & Qsar. Chicago, October 2012.
112) Viral Cancer Vaccines and Tumor Associted Antigens (TAA) in Immunotherapy, Preventive and Curative.BIT’s 6th Annual World Congress of Cancer. Xi’an, May 2013.
113) Human corin and Tumor Liberated Protein (TLP) in NSCL Cancer: Homology of different Isoforms in the Sequence at the Cell Surface. Bit’s 6th Annual World Congress of Cancer. Xi’an, Mag 2013.
114) Analysis of the Immunosuppressive Microenviroment in Human Breast Cancer. BIT’s Major Diseases Clinical Summit. Warsaw, November 2013.
115) State of Art in Lung Cancer Immunotherapy.BIT’s 2nd Lung Cancer Summit. Rome, December 2013.
116) State of Art on Cancer Vaccines, from Viruses to Tumor Associated Antigens (TAA).BIT’s 6th Annual World Congress of Vaccines. Dalian, April 2014.
117) Recent Advances in Lung Cancer Proteomics: Biomarkers Discovery.PepCon – BIT’s 7th Annual World Protein & Peptide. Dalian, April 2014.
118) New development on Tumor Associated Antigen with Specific Target.IBIO – BIT’s 7th Annual Congress of Industrial Biotechnology. Dalian, April 2014.
119) From viruses to tumor associated antigen cancer vaccines.OMICS 4th International Conference on Vaccine & Vaccination. Valencia, September 2014.
120) Vaccine Research and Development in Oncology.Global Conference on Vaccines. Dubai, April 2015.
121) Vaccine Research and Development in Oncology.BIT’s 7th Annual World Congress of Vaccine. Nanjing, April 2015.
122) Latest Progress on Lung cancer Proteomics.PepCon – BIT’s 8th Annual World Protein & Peptide Conference. Nanjing, April 2015.
123) Up to date on Tumor Liberated Protein (TLP): New Test at Hamburg.IBIO – BIT’s 8th Annual World Congress of Industrial Biotechnology. Nanjing, April 2015.
124) Analyzing the risk of Flu for understanding a better prevention. International Conference on Flu Hosted by OMICS International, Chicago, June 8-10-2015.
125) Oncogenic Viruses and Tumor Associated Antigens Vaccines International Conference on Vaccines Research and Development by Unted Scientific Group, Baltimore (USA, November 2-4, 2015.
126) Immunotherapy Perspetcives for Tumor Liberated Protein (TLP) from Non Small Cell Lung Cancer. 2nd International Lung Cancer Symposion. Budapest, Hungary. April 16-17, 2016.
127) Important topics on human vaccines and vaccination for non infections diseases. 8th Annual World Congress of Vaccine 2016 (WCV-2016) Dalian, China. April 25-28, 2016.
128) The recent and progressive studies on genetic analysis of TLP and its expression as complete protein sequence. The World DNA and Genome Day 2016 (WDD-2016). Dalian /China) April 25-28, 2016.
129) Isolation of the TLP enconding cDNA, gene sequence and analysis of its expression control. 9th annual World Protein and Peptide Conference – 2016 (Pep-Con, 2016). Dalian (China) April 25-28, 2016.
130) Human Vaccines and Vaccination for Non Infectious Diseases. 10th Euro Global Summit and Expo on Vaccines and Vaccination. Rome, June 16-17, 2016 (Honorable Organizing Committee Member).
131) Migratory Phenomena and Bioethics of the Vaccinations, 4th Annual Conference on Apllied Microbiology, September 19-21 2016 Las Vegas, USA (Organizing Committee Member).
132) A vaccine approaches with a tumor associated antigen for preventive and therapeutic application, Vaccine ReD 2016, November 10-12, 2016 Cartagena, Columbia.
133) Emerging Influenza Viruses at Risk in Global Health. “2nd International Conference on Flu”, San Francisco, USA. November 28-30, 2016 (Organizing Committee Member).
134) Emerging H1N1 Influenza A Virus and its Specific Prevention. Annual Conference on H1N1 and Influenza Vaccines, Atlanta, USA December 01-02, 2016 (Honorable Organizing Committee Member).
Biographical sketch of Giulio Tarro
Dr Tarro has been engaged in medical research for over 30 years. He was born on July 9 1938 inMessina, Sicily, where he attended High School, and in 1956 began his medical studies at Messina University and then in 1960 continued at NaplesUniversity from which he received his M.D. “summa cum laude» in 1962 and the professorship for Oncological Virology in 1972.
His research work began in 1960 in the virology laboratory of the department of Medical Pathology at the University of Naples and continued during the entire period of his medical studies. In I963 and 1964 he was at the Polyclinic of the University in Naples receiving training in pathology, neurology and internal medicine. In 1965 he went to the Children’s Hospital Research Foundation at the University of Cincinnati, where he worked with Dr Albert B. Sabin as a Research associate for three years and, subsequently, in 1968 and 1969 he was assistant Professor of Research Pediatrics at the same University. From there Dr Tarro went back to Naples and established a virology laboratory at the Hospital for Infectious Diseases with the help of a Research Contract from the National Cancer lnstitute (U.S.A.). In 1973 Dr Tarro worked as Senior Scientist at the Frederick Cancer Research Center with Dr Albert Sabin, who was then a special consultant for the National Cancer lnstitute. His most notable work provided experimental evidence for the association of herpes viruses with cancer of the cervix. Although at first controversial, this work has been carried out by several laboratories using different techniques.
Dr Tarro’s researches in Virology have been both basic and mission oriented. His basic researches have been concerned with antigens induced early during the replication cycle of herpes simplex virus (HSV). Specific antibodies were detected by the enzyme-Iinked immunosorbent assay in the serum of patients affected with certain carcinomas of the head, neck and urogenital tract. His mission-oriented research has dealt with many aspects of various infectious diseases including broncho-pneumonia, encephalitis, cholera, and the diseases caused by different viruses.
During 1979 he was engaged in research on an epidemic disease in Naples called the “dark disease”. Dr Tarro isolated the respiratory syncytial virus (RSV) and found antibody evidence that this virus was behind the epidemic. The World Heath Organization expert were called in and agreed most cases of disease were caused by RSV. In 1981 he suggested the proper use of interferon to cure the cytomegalovirus infection affecting the pope John Paul the second who underwent long surgicaI operation and received huge blood transfusion after the killing attempt.
Dr Tarro is currently engaged in scientific research related to the separation and identification of tumour antigens present on cell membranes and their potential value in immunotherapy for cancer. He has shown that specific soluble antigens may be used in various tests for a further understanding of their role in various cancer systems. Another study has involved the identification, isolation and characterization of specific virus-induced tumour antigens, which were the “finger-prints” left behind in tumours induced in man by human herpes viruses. IntramuraI activities have included being director of thesis and research for many candidates; director of medical research fellowships for medical students; participation in research planning for clinical colleagues; teaching virology, oncology and immunology to medicaI and graduate students.
He is on the editorial board of various Italian medical journals. Dr Tarro has been elected to membership of many academies and societies. He has also been the recipient of many awards and honours. Dr Tarro is life president of the T. and L. de Beaumont Bonelli Foundation for Cancer Research officially recognized by Italian presidential decree n. 36 of January 3, 1978. The aim of the Foundation is the promotion of scientific research on cancer and was instituted thanks to the generous donation of the late Teresa Berger who Ieft to the foundation a Iarge part of her patrimony, whereas the late husband, the EarI Luigi de Beaumont Bonelli, Ieft most of his patrimony to the Nobel foundation.
Son of Emanuele and Jannello Emanuela, his father was a doctor, an anatomic and clinical pathologist. His sister, Licia, teaches French and is married.
Dr Tarro was on his own since the age of twenty, making the Iiving on scholarships, and used his earnings to purchase books. He enjoys soccer, swimming and good food. His favourite hobbies are art history and sightseeing.
In 2007 Tarro has adopted one son, Giuseppe, expert in computing who is married with Antonella and they have a doughter, Giulia.